[sydd]

from OP's article:

> In the developing world, where healthcare resources, infrastructure and economics are so different, we have entered into agreements with generic manufacturers to deliver treatment at a substantially lower cost.

I assume this means that:

1. Remdesvir is not that hard to manufacture.

2. Gilead will license the drug to 3rd party factories, so no need to manufacture them in the US.